Cargando…

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

BACKGROUND: Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concomitant medications. The sodium glucose co-transporter 2 inhibitor, can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Michael J., Merton, Katherine, Vijapurkar, Ujjwala, Yee, Jacqueline, Qiu, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361783/ https://www.ncbi.nlm.nih.gov/pubmed/28327140 http://dx.doi.org/10.1186/s12933-017-0517-7

Ejemplares similares

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies, Michael J, et al.
Publicado: (2017)

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
por: Patel, Charmi A., et al.
Publicado: (2016)

Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
por: Gilbert, Richard E., et al.
Publicado: (2017)

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
por: Pfeifer, Michael, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
por: Sinclair, Alan, et al.
Publicado: (2014)

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
por: Leiter, Lawrence A., et al.
Publicado: (2016)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis
por: Besch, Guillaume, et al.
Publicado: (2019)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Association of Intensive Blood Pressure Control and Living Arrangement on Cardiovascular Outcomes by Race: Post Hoc Analysis of SPRINT Randomized Clinical Trial
por: Inoue, Kosuke, et al.
Publicado: (2022)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
por: Liu, Jie, et al.
Publicado: (2019)

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
por: Merola, Joseph F., et al.
Publicado: (2022)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
por: Paller, Amy S., et al.
Publicado: (2023)

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
por: von Eynatten, Maximilian, et al.
Publicado: (2013)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index
por: Khera, Rohan, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
por: Prasanna Kumar, K. M., et al.
Publicado: (2016)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
por: Leiter, Lawrence A., et al.
Publicado: (2019)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
por: Skelley, Jessica W, et al.
Publicado: (2018)

Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study
por: Udell, Jacob A., et al.
Publicado: (2019)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
por: Nasiri-Ansari, Νarjes, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_91d0500vi7lq4ifhq4tjg454r3